International Huntington Association - en global indsats for at hjælpe mennesker med Huntingtons sygdom

INTERNATIONAL HUNTINGTONFORENING

En global indsats for at hjælpe mennesker med Huntingtons sygdom

En paraplyorganisation uden gevinst for øje, der blev oprettet i 1974 af Marjorie Guthrie. Den repræsenterer nu mere end 250 000 enkeltpersoner og medlemsforeninger over hele verden.

Få mere at vide om HD

INTERNATIONAL HUNTINGTONFORENING

For five decades, the International Huntington Association has been supporting the global HD community. Our 50th-anniversary celebration marks not only a milestone in our history but also the beginning of important new initiatives, projects aimed at furthering our impact, reaching ever more people and bringing hope and comfort to all.

Se, hvad vi har lavet

HD FOCUS: NEWS ACROSS THE GLOBE

A dedicated news platform that gathers the latest updates from local Huntington's disease associations and key global resources. Our goal is to provide the HD community with timely, relevant, and insightful news from across the world, helping families, caregivers, and advocates stay informed and connected. Stay up to date with the latest advancements in research, support initiatives, and community stories.

Visit HD Focus

HD BLOG

HD is a complex disease, and even with a lot of information available today, we believe that something is missing: personal stories. Feelings, advice, choices, ideas, indecision, mechanisms, and thoughts all need a space to be shared. Therefore, HD Blog was created to provide such a place. The community is essential because it helps us understand that we are not alone in our struggles as others feel the same way we do.

Read HD Blog

Forrige dias

Næste dias

Frivillig i IHA

Hvis du vil hjælpe folk med Huntingtons sygdom, leder vi efter folk, der er villige til at gå sammen og skabe noget sammen.

Find mere

Vil du oprette din lokale forening?

Hvis du ønsker at starte din egen forening til støtte for HD, kan vi hjælpe dig med at forstå, hvordan

Lær hvordan

Du kan hjælpe os med at gøre en forskel

Din donation vil hjælpe os med at støtte personer og familier, der er ramt af HD

Donér

Seneste nyheder

Nyheder

11 december 2024

UniQure announces alignment with FDA on key elements of accelerated approval pathway for AMT-130

Yesterday, uniQure issued a press release announcing alignment with the US Food and Drug Administration (FDA) on key elements of an accelerated approval pathway...

Læs mere

Nyheder

09 december 2024

"The Present", documentary featuring Dimitri Poffé, is now available on Youtube

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South...

Læs mere

Nyheder

09 december 2024

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory...

Læs mere

Nyheder

09 december 2024

Sage Therapeutics ceases development of dalzanemdor in HD

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data,...

Læs mere

Nyheder

05 november 2024

Livable Lives - a new book that highlights stories from people impacted by HD around the world

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations...

Læs mere

Nyheder

02 oktober 2024

LoQus23 Therapeutics announces £35 million financing to advance a new drug aimed at inhibiting somatic expansion in Huntington's Disease

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF)...

Læs mere

Nyheder

26. september 2024

FDA giver Fast Track-status til PTC518 Huntingtons sygdomsprogram

PTC518 er en oral medicin, der reducerer produktionen af det muterede Huntingtin-protein, som forårsager sygdomsprogression. Programmer...

Læs mere

Nyheder

03. september 2024

Prilenias pridopidin til Huntingtons sygdom godkendt til gennemgang af europæisk markedsføringstilladelse

Prilenia, en bioteknologisk virksomhed i den kliniske fase med fokus på den presserende mission at udvikle nye behandlingsmetoder til at bremse udviklingen af neurodegenerative sygdomme...

Læs mere

Historier

01. august 2024

Krønike om en ubarmhjertig søgen: Skabelsen af et fundament

Jeg tilhører tredje generation af en familie, der er ramt af Huntingtons sygdom, men det var først i 2024, takket være min anden fars utrættelige indsats, at...

Læs mere

Nyheder

11 juli 2024

IROS, Prilenia og International Huntington's Disease Association samarbejder om det første forsøg med Huntingtons sygdom (HS) nogensinde i MENA-regionen

Et skelsættende forsøg har til formål at bringe pridopidin, en innovativ ny behandling af Huntingtons sygdom (HS), ud til patienter i regionen. Det vil hjælpe med at øge bevidstheden...

Læs mere